CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Integrated analysis of bulk and single-cell RNA sequencing reveals the interaction of PKP1 and tumor-infiltrating B cells and their therapeutic potential for nasopharyngeal carcinoma.
Integrated analysis of bulk and single-cell RNA sequencing reveals the interaction of PKP1 and tumor-infiltrating B cells and their therapeutic potential for nasopharyngeal carcinoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
免疫治疗是鼻咽癌(NPC)的一种个体化治疗策略。然而,临床上令人满意的分子靶点很少。本研究旨在整合批量与单细胞RNA测序数据,以识别参与NPC的新型生物标志物。
我们进行了差异表达基因(DEG)分析、基因本体(GO)富集分析、京都基因与基因组百科全书(KEGG)通路分析以及免疫细胞浸润分析,随后对已识别的基因与免疫细胞进行相关性分析,并进一步评估生物标志物和免疫细胞在NPC中的预后影响。结果,PKP1——一个与免疫浸润相关的潜在分子生物标志物——以及TIL(肿瘤浸润淋巴细胞)-B细胞(TIL-Bs)被确定为NPC有前景的治疗靶点。
重要的是,免疫组织化学(IHC)证实PKP1蛋白表达主要见于NPC细胞而非非癌细胞。此外,NPC的肿瘤微环境(TME)以更多树突状细胞(DCs)和T细胞浸润但B细胞较少为特征。
我们的结果提示PKP1与TIL-B细胞的相互作用参与NPC的发生发展。TIL-B细胞可能产生针对肿瘤抗原(如PKP1)或病毒抗原(包括EBV和HPV)的免疫球蛋白G(IgG),通过DC和T细胞发挥抗肿瘤能力。作为回应,NPC细胞表达诸如PKP1(正常鼻咽中不存在)等蛋白,以诱导髓源性抑制细胞(MDSC)扩增,随后通过产生iNOS和NOX2损害B细胞增殖并导致B细胞死亡。
总之,我们的发现通过破坏TME中PKP1与TIL-Bs的相互作用,为NPC提供了一种潜在的治疗策略。
Immunotherapy is an individualized therapeutic strategy for nasopharyngeal carcinoma (NPC).
However, few molecular targets are clinically satisfactory. This work aimed to integrate bulk and single-cell RNA sequencing data to identify novel biomarkers involved in NPC.
We performed differentially expressed gene (DEG) analysis, Gene Ontology (GO) enrichment, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis, and immune cell infiltration analysis prior to correlation analysis of the identified genes and immune cells and further assessed the prognostic effects of the biomarkers and immune cells in NPC. As a result, PKP1, a potential molecular biomarker associated with immune infiltration, and tumor-infiltrating lymphocyte-B cells (TIL-Bs) were identified as promising therapeutic targets for NPC.
Importantly, immunohistochemistry (IHC) validated that PKP1 protein expression was mainly found in NPC cells rather than noncancerous cells.
In addition, the tumor microenvironment (TME) of NPC was characterized by the infiltration of more dendritic cells (DCs) and T cells but fewer B cells.
Our results suggest that the interaction of PKP1 and TIL-B cells is involved in NPC development. It is possible that TIL-B cells produce immunoglobulin G (IgG) to tumor antigens, such as PKP1, or viral antigens, including EBV and HPV, to execute antitumor ability through DC and T cells.
In response, NPC cells express proteins such as PKP1 (absent in normal nasopharynx) to induce myeloid-derived suppressor cell (MDSC) expansion, which subsequently impairs the proliferation of B cells and results in B-cell death by generating iNOS and NOX2. In summary, our findings provide a potential therapeutic strategy for NPC by disrupting the interaction of PKP1 and TIL-Bs in the TME.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。